At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven, previously untreated stage III or IV squamous cell carcinoma of the larynx
- ✓Primary tumor stage T2 or T3 with any nodal stage (N0, N1, N2, N3)
- ✓Measurable disease by RECIST 1.1
- ✓ECOG performance status 0 or 1
- ✕T1 primary tumor
- ✕T4 large volume tumor causing laryngeal dysfunction at baseline (e.g., penetration into base of tongue with swallowing impairment)
- ✕Prior radiation therapy to the larynx or involved neck
- ✕Distant metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, Radiation Therapy, and 1 other intervention for Head and Neck Cancer. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for larynx cancer. The standard of care treatment will include chemotherapy and radiation for 7 weeks.
Study Details
Timeline
Interventions
200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
70 Gy in 35 fractions over 7 weeks
100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.